Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Developmental therapeutics

1429 - Initial results from a phase 1/2a trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer


21 Oct 2018


Proffered paper session - Developmental therapeutics


Cytotoxic Therapy;  Clinical Research

Tumour Site


John Hilton


Annals of Oncology (2018) 29 (suppl_8): viii133-viii148. 10.1093/annonc/mdy279


J. Hilton1, M.C. Cristea2, M. Voskoboynik3, S. Postel-Vinay4, W. Edenfield5, A. Gavai6, S. Wee6, N. Srivastava6, A. Klippel7, D. Jackson6, A. Apfel6, S.D. Chasalow8, D. Williams6, M. Donovan6, B. Fischer9, S. Khaldoyanidi6, J.R. Diamond10

Author affiliations

  • 1 Division Of Medical Oncology, The Ottawa Hospital Regional Cancer Centre, K1H 8L6 - Ottawa/CA
  • 2 Department Of Medical Oncology & Therapeutics Research, City Of Hope National Medical Center, 91010 - Duarte/US
  • 3 Department Of Oncology, Nucleus Network, Monash University, Victoria/AU
  • 4 Department Of Drug Development, Institut de Cancérologie Gustave Roussy, 94800 - Villejuif/FR
  • 5 Internal Medicine, GHS Cancer Institute, Greenville Health System, Greenville/US
  • 6 Immuno-oncology, Bristol-Myers Squibb, Princeton/US
  • 7 Immuno-oncology, Bristol-Myers Squibb, 08640 - Princeton/US
  • 8 Immuno-oncology, Bristol-Myers Squibb, 08540 - Princeton/US
  • 9 Immuno-oncology, Bristol-Myers Squibb, NJ 08648 - Princeton/US
  • 10 Division Of Medical Oncology, University of Colorado School of Medicine, Aurora/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1429


Tumor cells harboring select genetic abnormalities (eg, BRD3/4-NUT) have shown sensitivity to BET inhibition. BMS-986158, a potent, selective and orally bioavailable BET inhibitor (BETi) was active in several established and pt-derived tumor xenograft models (Gavai AV, et al. AACR 2018; Wee S, et al. AACR 2018). Here we present initial data for BMS-986158 monotherapy from a phase 1/2a trial in previously treated pts with advanced cancer (NCT02419417).


During dose escalation, pts received BMS-986158 (0.75, 1.25, 2.0, 3.0, or 4.5 mg) once daily across 3 schedules: A (5 days on/2 days off), B (14 days on/7 days off), or C (7 days on/14 days off). Pharmacokinetics (PK), pharmacodynamics, and safety were evaluated.


As of March 20, 2018, 68 pts (median age, 59) received BMS-986158 (A [n = 31], B [n = 8], or C [n = 29]); 43% of pts had ≥ 4 prior therapies. Initial PK analysis of BMS-986158 showed dose-proportional and linear increase in exposure, with fast absorption (Tmax 2-4 h), long half-life (T1/2 33-82 h), and dose-dependent AUC. Treatment(tx)-related AEs (TRAEs) occurred in 63% of pts (Gr 3-4, 22%). TRAEs (any Gr; Gr 3-4) reported in ≥ 15% of pts were mild diarrhea (34%; 0%), thrombocytopenia (28%; 15%), and fatigue (16%; 1.5%). No tx-related deaths or discontinuations due to a TRAE occurred. The dose-limiting toxicity (DLT) was Gr 3-4 thrombocytopenia. Effects of BMS-986158 on gene transcription for biomarkers of BET activity (eg, CCR2 and HEXIM1) in peripheral blood cells were dose dependent and reversible with the 4.5-mg dose resulting in the highest change in gene expression. Of 4 pts with NUT midline carcinoma, an aggressive and fatal disease, 1 pt with a BRD3-NUT fusion received BMS-986158 (2.0 mg, schedule A) for 279 days, with best overall response of stable disease and 16% reduction in tumor burden, providing further evidence of target-mediated effects.


BMS-986158 was well tolerated, with reversible thrombocytopenia as the only DLT. This safety profile together with initial PK findings and effect on target gene expression support the ongoing evaluation of BMS-986158 in pts with select advanced cancers.

Clinical trial identification

Legal entity responsible for the study

Bristol-Myers Squibb.


Bristol-Myers Squibb.

Editorial Acknowledgement

Writing and editorial assistance was provided by Kathy Covino, PhD of Chrysalis Medical Communications, Inc., funded by Bristol-Myers Squibb.


J. Hilton: Advisory board: Bristol-Myers Squibb, AstraZeneca, Novartis, Pfizer, Eli-Lilly. A. Gavai, S. Wee, N. Srivastava, A. Klippel, D. Jackson, A. Apfel, S.D. Chasalow, D. Williams, M. Donovan, B. Fischer, S. Khaldoyanidi: Employment: Bristol-Myers Squibb; Stock ownership: Bristol-Myers Squibb. J.R. Diamond: Grants: Bristol-Myers Squibb, Bayer, Millennium Takeda, Immunomedics, Merck, Taiho, Rexahn. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.